ISPOR - HPR100 Analysis of the Drug Price Level of Anticancer and Rare Disease Drugs After the Implementation of Economic Evaluation Exemption in South Korea

HPR100 Analysis of the Drug Price Level of Anticancer and Rare Disease Drugs After the Implementation of Economic Evaluation Exemption in South Korea

Abstract

Authors

K Park YH Cho JR Gong

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now